Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

MGNX

Live52w high -2.3%

Annual Quarterly

Core line items from MGNX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: MACROGENICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$15.76M	$20.77M	$149.50M	$108.27M	$35.43M
Operating Income	Not available	$-33.44M	$-72.84M	$-60.74M	$-79.38M
Net Income	Not available	$-36.77M	$-74.62M	$-60.47M	$-36.25M
EPS (Diluted)	$-0.57	$-0.58	$-1.18	$-0.96	$-1.23
Total Assets	Not available	$217.87M	$256.85M	$270.76M	$245.42M
Total Liabilities	Not available	$196.68M	$201.25M	$203.76M	$198.80M
Cash & Equivalents	Not available	$66.52M	$57.22M	$80.13M	$130.69M
Free Cash Flow OCF − CapEx	Not available	$-36.16M	$-82.95M	$-125.73M	$-95.12M
Shares Outstanding	Not available	63.56M	63.32M	63.26M	63.21M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from MGNX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -2.3%

Entity: MACROGENICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-12	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$15.76M	$20.77M	$149.50M	$108.27M	$35.43M
Operating Income	Not available	$-33.44M	$-72.84M	$-60.74M	$-79.38M
Net Income	Not available	$-36.77M	$-74.62M	$-60.47M	$-36.25M
EPS (Diluted)	$-0.57	$-0.58	$-1.18	$-0.96	$-1.23
Total Assets	Not available	$217.87M	$256.85M	$270.76M	$245.42M
Total Liabilities	Not available	$196.68M	$201.25M	$203.76M	$198.80M
Cash & Equivalents	Not available	$66.52M	$57.22M	$80.13M	$130.69M
Free Cash Flow OCF − CapEx	Not available	$-36.16M	$-82.95M	$-125.73M	$-95.12M
Shares Outstanding	Not available	63.56M	63.32M	63.26M	63.21M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.